GameSpot may get a commission from retail offers. If you backed Hollow Knight on Kickstarter in late 2014, developer Team Cherry has confirmed that you will receive a download code for Hollow Knight: ...

Plus: Elon Musk tried to persuade Mark Zuckerberg to invest in OpenAI This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of ...

If Windows is your OS of choice, consider these open-source apps. There are tons of open-source apps for just about any task. These are all free to install and use on Windows. I've been using ...

SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its ...

Google confirmed the 100 million milestone exclusively to CNET. Here's what's coming next for Flow and its AI-assisted creators. Katelyn is a writer with CNET covering artificial intelligence, ...

The FBI is warning people of a new scam involving fake packages with QR codes designed to steal data. If people scan the code on a package they were not expecting, it prompts them to provide personal ...

CNN unveiled a slate of new programming for CNN Headlines, its domestic FAST channel. The new shows include CNN Headline Express, hosted by Brad Smith, that will include the latest national and ...

A program aimed at helping Black residents trace their ancestry, and in some cases, reconnect with living relatives in Africa, is expanding across the state of Illinois. The Illinois Family Roots ...

LOS ANGELES (KABC) -- The California Air Resources Board recently launched a first-of-its-kind program to gather hyper-local air pollution data that should help in the ongoing effort to improve air ...

Today Microsoft is incorporating GPT-5, OpenAI’s best AI system to date, into a wide variety of its products, to bring new reasoning capabilities and improvements to coding and chat across its ...

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, citing poor data and tough competition. Pfizer's last remaining GLP-1 agonist, ...